All In Biotech

Drug Trial Radar · NCT06562543

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

A Single Arm Phase 4 Trial to Evaluate the Safety and Efficacy of Oral Fruquintinib in the Treatment of Refractory Metastatic Colorectal Cancer in Patients From Minority Populations Underrepresented in Prior Fruquintinib Studies

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Jan 14, 2025

Primary completion

Oct 4, 2027

Study completion Oct 4, 2027

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Aug 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants. Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion.

Conditions

  • Colorectal Cancer

Interventions

  • FruquintinibDrug

    Oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Grade 3 and Grade 4 HypertensionTime frame: From the first dose of the study drug up to end of study (approximately 35 months)

Locations

45 sites in 2 countries. Site status is shown where the registry gives one.

  • Central Alabama Research

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Ironwood Cancer and Research Centers

    Chandler, Arizona · Recruiting

  • University of Arizona

    Tucson, Arizona · Recruiting

  • University of California San Diego

    La Jolla, California · Recruiting

  • University of Southern California

    Los Angeles, California · Recruiting

  • PIH Health Whittier Hospital

    Whittier, California · Recruiting

  • Christiana Care Health Services

    Newark, Delaware · Recruiting

  • University of Florida

    Gainesville, Florida · Completed

  • University of Miami

    Miami, Florida · Withdrawn

  • Baptist Health - Miami Cancer Institute

    Miami, Florida · Withdrawn

  • Emory University

    Atlanta, Georgia · Recruiting

  • Hope and Healing Cancer Services

    Hinsdale, Illinois · Recruiting

  • Indiana University

    Indianapolis, Indiana · Recruiting

  • Our Lady of the Lake Physician Group - LSU Health Baton Rouge Oncology

    Baton Rouge, Louisiana · Recruiting

  • Willis Knighton Cancer Center

    Shreveport, Louisiana · Recruiting

  • Mercy Medical Center

    Baltimore, Maryland · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Withdrawn

  • Hattiesburg Clinic

    Hattiesburg, Mississippi · Recruiting

  • Saint Luke's Cancer Institute

    Kansas City, Missouri · Withdrawn

  • Midwest Oncology Associates - Kansas City

    Kansas City, Missouri · Recruiting

  • SSM Health St. Louis DePaul Hospital

    St Louis, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Capital Health Medical Center - Hopewell

    Pennington, New Jersey · Recruiting

  • Columbia University

    New York, New York · Withdrawn

  • Albert Einstein College of Medicine

    The Bronx, New York · Withdrawn

  • James J Peters Veterans Administration Medical Center - NAVREF

    The Bronx, New York · Withdrawn

  • Zangmeister Cancer Center

    Columbus, Ohio · Recruiting

  • Hightower Clinical Research

    Oklahoma City, Oklahoma · Completed

  • Jefferson Health

    Philadelphia, Pennsylvania · Recruiting

  • Fox Chase Cancer Center | Philadelphia, PA

    Philadelphia, Pennsylvania · Withdrawn

  • Medical University of South Carolina

    Charleston, South Carolina · Withdrawn

  • University of Tennessee -- Memphis

    Memphis, Tennessee · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Renovatio Clinical

    El Paso, Texas · Recruiting

  • Oncology Consultants - Memorial City Location

    Houston, Texas · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • BRCR Global

    Katy, Texas · Withdrawn

  • Renovatio Clinical

    The Woodlands, Texas · Recruiting

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.